Back to search
Scientific Name: Umbralisib
Brand Name: UKONIQ
Company Owner: Not Available
Mechanism Of Action The PI3K pathway is a deregulated in malignancies, leading to the overexpression of p110 isoforms (p110α, p110β, p110δ, p110γ) that induces malignant transformation in cells.
Description of the Drug: Umbralisib is a kinase inhibitor used to treat rare forms of refractory lymphoma.
Protein Data Bank: Not Available
Source: DrugBank Online – Retrieved 2023-01-23 from